St. Jude Medical (STJ) is an innovation-driven company with a leading position in the heart failure device market. It has a comprehensive and diversified portfolio of products for the treatment of advanced heart diseases and chronic pain conditions.
The company was trading at $58.68 as of April 15, 2016. It has a 50-day moving average of $54.45 and a 200-day moving average of $62.75.
As of April 15, 2016, Thermo Fisher stock was trading 20.2% above its 52-week low and 27.4% below its 52-week high. The company’s stock has risen ~8.1% since its last quarterly earnings released on January 27, 2016. St. Jude Medical stock has returned -13.4% over the last 12 months. Its six-month returns were 6.9%.
Peer stock performance
As of April 15, 2016, peer companies Medtronic (MDT), Boston Scientific (BSX), and Edward Lifesciences (EW) generated returns of 0.80%, 5.8%, and 52.3%, respectively, over the last year. The Health Care Select Sector SPDR ETF (XLV) invests 0.64% of its total portfolio in St. Jude Medical. XLV has an exposure of ~17% to the medical device and technology industry.
In this series, we’ll be looking at St. Jude Medical’s market position and growth strategy. We’ll also look at its potential growth opportunities, performance, and potential across various product segments. These segments include cardiac rhythm management, atrial fibrillation, and heart failure devices. We’ll also cover St. Jude’s acquisition of Thoratec, the largest acquisition in the company’s history. Finally, we’ll see analyst estimates and recommendations as well as the company’s innovation and capital allocation strategy.
Let’s start by looking at St. Jude’s market position and opportunities.